WX-293
WX-293 is a highly selective urokinase-type plasminogen activator (uPA) inhibitor with a Ki value of 2.4 μM. WX-293 abolishes hypoxia-induced keratinocyte migration and in vitro wound closure. WX-293 can be used in research on hypoxia-mediated skin wounds and solid malignant tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 282718-42-7
- 分子式: C19H27N5O
- 分子量:341.45
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
WX-293 (0.1-0.2 μM; 16 h) inhibits hypoxia-induced in vitro wound healing of PAM 212 mouse keratinocytes in a concentration-dependent manner[1].
WX-293 potently and selectively inhibits purified human urokinase-type plasminogen activator (uPA) with a Ki value of 2.4 µM, and its mechanism of action involves targeting the S1′ pocket of uPA via a non-traditional binding mode[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PAM 212 murine keratinocytes
-
Concentration:0.1 μM, 0.2 μM
-
Incubation Time:16 h
-
Result:Inhibited hypoxia-enhanced wound closure by 70% (0.1 μM).
Inhibited uPA activity by 55.3% (0.1 μM).
Completely abolished hypoxia-enhanced wound closure (0.2 μM).
Inhibited uPA activity by 74.0% (0.2 μM).
Exhibited no effect on wound closure in normoxic cultures at either concentration.
化学情報
-
CAS 番号 282718-42-7
-
分子量 341.45
-
分子式 C19H27N5O
-
SMILES
O=C(NC12CC3CC(C2)CC(C1)C3)NCC4=CC=C(NC(N)=N)C=C4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Daniel RJ, et al. Increased migration of murine keratinocytes under hypoxia is mediated by induction of urokinase plasminogen activator. J Invest Dermatol. 2002;119(6):1304-1309. [Content Brief]
[2]. Muehlenweg B, et al. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin Biol Ther. 2001;1(4):683-691. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
WX-293 関連分類
HY-182450 関連分類
Powered by Bioz